8-K current report · filed Oct 29, 2026

MERIT MEDICAL SYSTEMS INC (MMSI) 8-K Current Report: October 29, 2026

Item 2.02Item EX-99.1Item EX-99.2Item EX-99.3Item 7.01MMSI overview

Short answer

MERIT MEDICAL SYSTEMS INC (MMSI) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 7.01 (Regulation FD Disclosure). Q3 2026 earnings release for quarter ended September 30, 2026.

MERIT MEDICAL SYSTEMS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 earnings release for quarter ended September 30, 2026
  • Results and management commentary available in Exhibit 99.1, relevant for updating revenue, profitability and outlook expectations

Item 7.01 · Regulation FD Disclosure

  • Q3 2026 results covered quarter ended September 30, 2026, with conference call and presentation on October 29, 2026
  • Solo Pace acquisition closed October 13, 2026 for approximately $45 million cash
  • Transaction expands Merit’s portfolio, with acquisition-related costs potentially affecting GAAP results
  • Management presented non-GAAP results, but excludes certain acquisition, amortization, litigation and compensation impacts from forward-looking GAAP guidance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $416.2M, up 8.4%, with 9% organic constant-currency growth, signaling broad underlying demand strength
  • GAAP operating margin 14.1% vs 11.1%, while non-GAAP margin reached 21.3% vs 19.7%, indicating improved operating leverage
  • GAAP EPS $0.70, up 51%, and non-GAAP EPS $1.12, up 22%, materially ahead of revenue growth
  • Therapeutic revenue rose 14%, led by Endoscopy up 33% and Therapeutic OEM up 32%; Foundational growth was 6%
  • 2026 guidance raised: revenue $1.635-$1.642B and non-GAAP EPS $4.33-$4.37, with cash $503.6M and debt $747.5M at September 30

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $416.2M, up 8.4% year over year, with domestic growth of 11.0% outpacing international growth of 4.4%
  • GAAP operating margin 14.1% versus 11.1%, while net income rose 52.4% to $42.3M and EPS increased 51.3% to $0.70
  • Non-GAAP EPS $1.12, up 21.7%, indicating stronger underlying earnings despite acquisition, amortization, and debt-related adjustments
  • Operating cash flow fell to $65.3M from $75.0M, a key counterpoint to the earnings improvement
  • 2026 guidance raised: revenue $1.635B-$1.642B and non-GAAP EPS $4.33-$4.37, with constant-currency growth of 7.0%-7.5%

Item EX-99.3 · Exhibit EX-99.3

  • Merit acquired Solo Pace’s remaining equity on October 13, 2026 for approximately $45 million, following its prior 18% ownership
  • Adds proprietary temporary pacing systems for TAVR and other transcatheter heart-valve procedures to Merit’s Cardiac Therapies platform
  • 2026 financial impact immaterial, limiting near-term earnings significance despite strategic portfolio expansion
  • 2027 non-GAAP earnings slightly accretive, including approximately $1.5 million lower interest income and excluding $3.2 million transaction expenses
  • 2027 GAAP earnings slightly dilutive, with accretion expected thereafter contingent on commercialization and integration execution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MERIT MEDICAL SYSTEMS INC 8-K filings

Get the next MMSI 8-K as it lands

Follow MMSI for push alerts, or ask the research agent what this filing means.